Galectin Therapeutics Inc. (NASDAQ: GALT) is a Healthcare company (Biotechnology) with a market capitalization of $192M. The Maz Rating grades it against the other companies in its sector.
Galectin Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
Galectin Therapeutics Inc. has been loss-making over the last twelve months, so it has no meaningful P/E. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of 21.7%, return on invested capital of 9066.7% and a free cash flow yield of -7.6%. On the balance sheet: a debt-to-equity ratio of -0.95 and a current ratio of 0.28. Over the past 52 weeks the share price ranged from $2.03 to $7.13, with a beta of 0.38.
Galectin Therapeutics Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.